Federal Pharmaceutical Posts Profit, Surges Over 10% Expected Mid-Year Net Profit to Be Around HK$18.5 Billion

Federal Pharmaceutical (03933) posted a profit, surging over 10%. As of the date of publication, the stock price has risen by 5.29%, currently trading at HK$17.12, with a turnover of HK$7.988 billion.

On August 18, Federal Pharmaceutical released an announcement, expecting its net profit for the six months ended June 30, 2025 to be approximately HK$18.5 billion, whereas the same period in 2024 saw a net profit of approximately HK$14.91 billion.

The announcement stated that the increase in net profit was mainly due to the license fee income from Nord Pharma AS's net profit of approximately HK$11 billion. However, compared to the same period last year, the intermediate product department saw a decline of around HK$4.3 billion, and the original material drug department saw a decline of around HK$2.7 billion, which partially offset this growth.